AZD6738

AZD6738 is a selective inhibitor of the enzyme ATR (Ataxia Telangiectasia and Rad3-related protein). ATR is a protein kinase that plays a crucial role in the DNA damage response pathway, which is responsible for maintaining the integrity of genetic material in cells. This pathway is activated in response to various types of DNA damage, such as UV radiation, chemical agents, and radiation. AZD6738 has shown promising results in preclinical studies as a potential cancer treatment as it enhances the sensitivity of cancer cells to radiation therapy and chemotherapy. It has also demonstrated efficacy in combination with other cancer drugs, such as PARP inhibitors, in reducing tumor growth. The chemical structure of AZD6738 is a pyrazolo[3,4-d]pyrimidine derivative, with a molecular weight of 407.42 g/mol. It is administered orally in capsule form, with recommended dosages varying according to the specific cancer being treated and the individual patient's response. While AZD6738 has shown promising results in preclinical studies, clinical trials are ongoing to further evaluate its safety and efficacy. Adverse effects reported in early studies include mild to moderate gastrointestinal symptoms, such as nausea, vomiting, and diarrhea. In conclusion, AZD6738 is a selective inhibitor of ATR that shows potential as a cancer treatment by sensitizing cancer cells to radiation therapy and chemotherapy. Ongoing clinical trials will help to determine its safety and effectiveness in treating various types of cancer.